First AD

Second AD

EMERALD Study Design and Results for Elacestrant 

Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (

How have the EMERALD trial impacted your use of Elacestrant in clinical practice, particularly in terms of patients’ selection and treatment sequencing?

What are your impressions of the overall and subgroup data from EMERALD? Does it expand the ideal patient population for elacestrant?

For a patient with metastatic breast cancer to bones, liver, and lungs who has an ESR1 mutation, how does this inform treatment selection between continuing endocrine therapy versus switching to other targeted agents or chemotherapy?

Would elacestrant be an ideal next line treatment for this patient?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies   

Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice. 